NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)

NCT02371967

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Basal Cell Carcinoma

Interventions: Vismodegib

Countries: Sweden

This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of vismodegib and to assess actual day-to-day disease and participant management by the physician.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* BCC that meets one of the study's pre-specified cohort definitions
* Physician's decision to treat participant with vismodegib as per local label
* Participant who has not participated in a clinical trial within 90 days prior to study enrollment, with the exception of participants who meet the criteria for Cohort 2 (No Gorlin Syndrome Participants With Prior HPI Exposure)

Exclusion Criteria:

* Female participants are excluded if they are pregnant or if they plan to become pregnant during treatment or within 2 years after end of treatment
* Male participants with female partners of childbearing potential are excluded if they plan to impregnate their partner during treatment or within 2 months after end of treatment

Locations (4)

Gothenburg, Sweden
Lund, Sweden
Solna, Sweden
Umeå, Sweden